We are live on ! Find out more
ASND icon

Ascendis Pharma A/S
ASND

203 hedge funds and large institutions have $8.28B invested in Ascendis Pharma A/S in 2024 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 75 increasing their positions, 67 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

65% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 23

12% more repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 67

7% more funds holding

Funds holding: 189 → 203 (+14)

6% more funds holding in top 10

Funds holding in top 10: 16 → 17 (+1)

0.19% less ownership

Funds ownership: 105.35% → 105.16% (-0.19%)

10% less capital invested

Capital invested by funds: $9.19B → $8.28B (-$914M)

52% less call options, than puts

Call options by funds: $21.1M | Put options by funds: $43.9M

Holders
203
Holders Change
+14
Holders Change %
+7.41%
% of All Funds
2.93%
Holding in Top 10
17
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+6.25%
% of All Funds
0.25%
New
38
Increased
75
Reduced
67
Closed
23
Calls
$21.1M
Puts
$43.9M
Net Calls
-$22.8M
Net Calls Change
-$19.3M

Top Buyers

1
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$121M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$83.1M
3
Ameriprise
Ameriprise
Minnesota
+$82.4M
4
Fidelity International
Fidelity International
Bermuda
+$58.7M
5
ACA
Avoro Capital Advisors
New York
+$31.3M

Top Sellers

1
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
-$345M
2
Artisan Partners
Artisan Partners
Wisconsin
-$187M
3
Brown Advisory
Brown Advisory
Maryland
-$27.9M
4
TD Asset Management
TD Asset Management
Ontario, Canada
-$18.6M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$18.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
Manulife (Manufacturers Life Insurance)
76
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$6.51M -$927K -6,814 -12%
RCAP
77
Resolute Capital Asset Partners
Colorado
$6.41M – – –
Schroder Investment Management Group
78
Schroder Investment Management Group
United Kingdom
$6.13M +$6.11M +44,918 New
FLAM
79
First Light Asset Management
Minnesota
$4.93M +$4.92M +36,157 New
State Street
80
State Street
Massachusetts
$4.78M +$95.9K +705 +2%
MC
81
Matisse Capital
Oregon
$4.74M -$110K -811 -2%
Tudor Investment Corp
82
Tudor Investment Corp
Connecticut
$4.55M +$4.54M +33,375 New
T. Rowe Price Investment Management
83
T. Rowe Price Investment Management
Maryland
$4.17M -$345M -2,538,339 -99%
Neuberger Berman Group
84
Neuberger Berman Group
New York
$4.13M +$4.12M +30,296 New
Marshall Wace
85
Marshall Wace
United Kingdom
$4.13M +$708K +5,205 +21%
DekaBank Deutsche Girozentrale
86
DekaBank Deutsche Girozentrale
Germany
$4.05M – – –
Citigroup
87
Citigroup
New York
$3.45M +$722K +5,305 +27%
ETCM
88
Evolutionary Tree Capital Management
Virginia
$3.39M +$1.53M +11,223 +82%
HJIM
89
Henry James International Management
New York
$3.34M -$3.27K -24 -0.1%
TI
90
Trexquant Investment
Connecticut
$3.23M +$464K +3,408 +17%
NIP
91
Nicholas Investment Partners
California
$3.17M +$712K +5,232 +29%
LIP
92
Lighthouse Investment Partners
Florida
$2.76M +$2.76M +20,250 New
EAM
93
Exome Asset Management
New York
$2.73M +$2.72M +20,000 New
CCM
94
Cinctive Capital Management
New York
$2.64M -$3.95M -29,033 -60%
Barclays
95
Barclays
United Kingdom
$2.59M -$281K -2,068 -10%
EAM
96
Erste Asset Management
Austria
$2.5M – – –
VOYA Investment Management
97
VOYA Investment Management
Georgia
$2.41M -$262K -1,925 -10%
CCIA
98
Campbell & Co Investment Adviser
Maryland
$2.35M +$2.35M +17,260 New
Jane Street
99
Jane Street
New York
$2.22M -$562K -4,133 -20%
UBS Group
100
UBS Group
Switzerland
$2.17M -$1.61M -11,834 -43%
2 3
4
5 6

ASND Hedge Fund Activity: Q2 2024 in Review

203 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q2 2024, worth a combined $8.28B — down 9.9% from $9.19B a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new ASND positions and 23 closed out — a net gain of 15 holders — while 75 added to existing stakes and 67 trimmed.

The largest buyer was Westfield Capital Management, adding an estimated $121M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $345M.

  • 203 institutional investors held Ascendis Pharma A/S (ASND) as of Q2 2024, up from 189 in Q1 2024.
  • Funds reported $8.28B of Ascendis Pharma A/S stock for Q2 2024, down 9.9% quarter-over-quarter.
  • 38 funds opened new Ascendis Pharma A/S positions in Q2 2024 and 23 closed out, a net change of +15 holders.
  • The largest Ascendis Pharma A/S buyer in Q2 2024 was Westfield Capital Management, an estimated $121M added.
  • The largest Ascendis Pharma A/S seller in Q2 2024 was T. Rowe Price Investment Management, an estimated $345M sold.

Based on aggregated 13F filings for Q2 2024.